Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study

Journal of the American College of Cardiology

Volumn 56, Issue 3, 2010, Pages 185-193

  Storey, Robert F ^a   Bliden, Kevin P ^b   Patil, Shankar B ^a   Karunakaran, Arun ^a   Ecob, Rosemary ^a   Butler, Kathleen ^c   Teng, Renli ^c   Wei, Cheryl ^c   Tantry, Udaya S ^b   Gurbel, Paul A ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

adenosine diphosphate; ADP; area under the plasma concentration time curve over 8 hours; AUC08; C max; CAD; coronary artery disease; CYP; cytochrome P450; FEV 1; forced expiratory volume at 1 s; forced vital capacity; FVC; maximum plasma drug concentration

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CLOPIDOGREL; PLACEBO; TICAGRELOR; ACETYLSALICYLIC ACID; ADENOSINE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART FUNCTION; HUMAN; INCIDENCE; LOADING DRUG DOSE; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEART; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY;

ADENOSINE; AGED; ASPIRIN; CORONARY DISEASE; DOUBLE-BLIND METHOD; DYSPNEA; FEMALE; HEART; HUMANS; LUNG; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; TICLOPIDINE;

EID: 77955110385     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.01.062     Document Type: Article

References (9)

1. 12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation J Thromb Haemost 7 2009 1556 1565
2. 12 receptor Curr Pharm Des 12 2006 1255 1259
3. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
4. S. Husted, H. Emanuelsson, S. Heptinstall, P.M. Sandset, M. Wickens, and G. Peters Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin Eur Heart J 27 2006 1038 1047
5. C.P. Cannon, S. Husted, and R.A. Harrington Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial J Am Coll Cardiol 50 2007 1844 1851
6. J.-A. Bjorkman, I. Kirk, and J.J. van Giezen AZD6140 inhibits adenosine uptake into erythrocytes and enhances coronary blood flow after local ischemia or intracoronary adenosine infusion (abstr) Circulation 116 2007 II28
7. N.K. Burki, W.J. Dale, and L.Y. Lee Intravenous adenosine and dyspnea in humans J Appl Physiol 98 2005 180 185
8. P.A. Gurbel, K.P. Bliden, and K. Butler Randomized double-blind assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 121 2010 1169 1171
9. P. Gresele, J. Arnout, H. Deckmyn, and J. Vermylen Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity Thromb Haemost 55 1986 12 18